These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 15666996)
1. Design and construction of a phosphorylatable chimeric monoclonal antibody with a highly stable phosphate. Wu W; Kerrigan JE; Yadav P; Schwartz B; Izotova L; Lavoie TB; Pestka S Oncol Res; 2004; 14(11-12):541-58. PubMed ID: 15666996 [TBL] [Abstract][Full Text] [Related]
2. Construction of phosphorylatable chimeric monoclonal antibody CC49. Lin L; Gillies SD; Lan Y; Izotova L; Wu W; Schlom J; Pestka S Int J Oncol; 1998 Jul; 13(1):115-20. PubMed ID: 9625812 [TBL] [Abstract][Full Text] [Related]
3. Construction of phosphorylatable chimeric monoclonal antibody CC49 with a casein kinase I recognition site. Lin L; Gillies SD; Schlom J; Pestka S Protein Expr Purif; 1999 Feb; 15(1):83-91. PubMed ID: 10024474 [TBL] [Abstract][Full Text] [Related]
4. Construction of phosphorylatable monoclonal antibody CC49 with a casein kinase II recognition site. Lin L; Gillies SD; Schlom J; Pestka S Anticancer Res; 1998; 18(6A):3971-8. PubMed ID: 9891433 [TBL] [Abstract][Full Text] [Related]
5. Construction of phosphorylatable chimeric monoclonal antibody CC49 with a tyrosine srC kinase recognition site. Lin L; Gillies SD; Schlom J; Pestka S Int J Oncol; 1998 Oct; 13(4):725-32. PubMed ID: 9735402 [TBL] [Abstract][Full Text] [Related]
6. Construction of phosphorylatable monoclonal antibody to a tumor-associated antigen. Lin L; Daugherty B; Schlom J; Pestka S Cancer Res; 1996 Sep; 56(18):4250-4. PubMed ID: 8797600 [TBL] [Abstract][Full Text] [Related]
7. Construction and expression of two mouse-human chimeric antibodies with high specificity and affinity for carcinoembryonic antigen. Arakawa F; Haruno M; Kuroki M; Kanda H; Watanabe T; Misumi Y; Matsuoka Y Hybridoma; 1993 Aug; 12(4):365-79. PubMed ID: 8244416 [TBL] [Abstract][Full Text] [Related]
8. Protein kinase A: regulation and receptor-mediated delivery of antisense oligonucleotides and cytotoxic drugs. Sveshnikov PG; Grozdova ID; Nesterova MV; Severin ES Ann N Y Acad Sci; 2002 Jun; 968():158-72. PubMed ID: 12119275 [TBL] [Abstract][Full Text] [Related]
9. Construction and expression of chimeric antibodies by a simple replacement of heavy and light chain V genes into a single cassette vector. Kanda H; Mori K; Koga H; Taniguchi K; Kobayashi H; Sakahara H; Konishi J; Endo K; Watanabe T Hybridoma; 1994 Oct; 13(5):359-66. PubMed ID: 7860092 [TBL] [Abstract][Full Text] [Related]
10. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; Pepe S; Bianco AR; Agrawal S; Mendelsohn J; Tortora G J Natl Cancer Inst; 1998 Jul; 90(14):1087-94. PubMed ID: 9672257 [TBL] [Abstract][Full Text] [Related]
11. Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant. Hand PH; Calvo B; Milenic D; Yokota T; Finch M; Snoy P; Garmestani K; Gansow O; Schlom J; Kashmiri SV Cancer Immunol Immunother; 1992; 35(3):165-74. PubMed ID: 1638552 [TBL] [Abstract][Full Text] [Related]
12. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Scott AM; Geleick D; Rubira M; Clarke K; Nice EC; Smyth FE; Stockert E; Richards EC; Carr FJ; Harris WJ; Armour KL; Rood J; Kypridis A; Kronina V; Murphy R; Lee FT; Liu Z; Kitamura K; Ritter G; Laughton K; Hoffman E; Burgess AW; Old LJ Cancer Res; 2000 Jun; 60(12):3254-61. PubMed ID: 10866319 [TBL] [Abstract][Full Text] [Related]
13. New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Velders MP; Litvinov SV; Warnaar SO; Gorter A; Fleuren GJ; Zurawski VR; Coney LR Cancer Res; 1994 Apr; 54(7):1753-9. PubMed ID: 8137290 [TBL] [Abstract][Full Text] [Related]
14. Serine-53 at the tip of the glycine-rich loop of cAMP-dependent protein kinase: role in catalysis, P-site specificity, and interaction with inhibitors. Aimes RT; Hemmer W; Taylor SS Biochemistry; 2000 Jul; 39(28):8325-32. PubMed ID: 10889042 [TBL] [Abstract][Full Text] [Related]
17. Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions. Nichols P; Li L; Kumar S; Buck PM; Singh SK; Goswami S; Balthazor B; Conley TR; Sek D; Allen MJ MAbs; 2015; 7(1):212-30. PubMed ID: 25559441 [TBL] [Abstract][Full Text] [Related]
18. Cloning and characterization of a single-chain fragment of monoclonal antibody to ACE suitable for lung endothelial targeting. Balyasnikova IV; Berestetskaya JV; Visintine DJ; Nesterovitch AB; Adamian L; Danilov SM Microvasc Res; 2010 Dec; 80(3):355-64. PubMed ID: 20888351 [TBL] [Abstract][Full Text] [Related]
19. Contribution of the carboxyl-terminal regional of the cAMP-dependent protein kinase type I alpha regulatory subunit to cyclic nucleotide interactions. Kapphahn MA; Shabb JB Arch Biochem Biophys; 1997 Dec; 348(2):347-56. PubMed ID: 9434747 [TBL] [Abstract][Full Text] [Related]